Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Fast Track designation granted to one-time intravitreal gene therapy for geographic atrophy
➤ FDA clears IND for Stargardt gene therapy to move forward into a Phase 1/2 clinical trial
➤ BLA submission for retinitis pigmentosa gene therapy begins
➤ First patient dosed in Phase 1/2 trial evaluating NK therapy
➤ Enrollment complete in Phase 2b trial for PCED therapy
➤ ASCRS news and events
➤ Results from second Phase 3 pivotal trial for presbyopia drop
➤ Interim Phase 2 data presented on DME, wet AMD treatment
➤ Phase 2 trial to investigate oral DME treatment
➤ First patient dosed in investigational cell therapy for photoreceptor diseases
➤ Phase 1 trial begins for minimally invasive dry AMD treatment
➤ Acquisitions and other company news
➤ ASCRS news and events
➤ Initial Phase 3 results for dry eye disease therapy
➤ Positive Phase 2 results for intravitreal implant for glaucoma and diabetic retinopathy
➤ Phase 1/2a results from allogenic cell therapy for geographic atrophy
➤ Phase 1 trial successful with oral treatment for non-proliferative diabetic retinopathy
➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development ➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy ➤ First patient dosed in genome editing program for corneal dystrophy ➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development
➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy
➤ First patient dosed in genome editing program for corneal dystrophy
➤ ASCRS news and events
➤ FDA approves first-in-class DED drop
➤ FDA accepts NDA for topical presbyopia therapy
➤ TFOS DEWS III
➤ Topline results in Phase 3 study evaluating night driving impairment after keratorefractive surgery
➤ IND application submitted for pediatric myopia treatment
➤ Study sheds light on clinical inherited retinal diseases without genetic mutations
➤ ASCRS news and events
➤ Phase 2 results for autoimmune-related dry eye disease immunomodulator
➤ JCRS astigmatism working group publishes two papers
➤ FDA approves therapy for diabetic retinopathy
➤ Enrollment closes for largest retinal trial of its kind to date
➤ Enrollment complete for Phase 3 trial evaluating wet AMD treatment
➤ Rare Pediatric Disease Designation granted for treatment targeting several retinopathies
➤ ASCRS news and events
➤ Company to begin trial with dual-optic accommodative lens
➤ Phase 2 study to begin for immunoglobulin drops for dry eye
➤ Long-term durability of TED treatment demonstrated
➤ Positive Phase 1/2 data from study evaluating X-linked retinoschisis
➤ Eye drop recall
➤ ASCRS news and events
➤ Positive update from Phase 2 study evaluating oligonucleotide for AMD and DME
➤ 18-month data presented on novel drug delivery platform
➤ Phase 1/2a trial results for intravitreal injection for treatment of glaucoma
➤ Advancing AI to facilitate detection and improve management of ocular disease
➤ Fast Track designation granted for neuropathic corneal pain
➤ Regenerative Medicine Advanced Therapy designation granted to investigational gene therapy
➤ ASCRS news and events
